Menu Back toSpeakers

DIA Global Pharmacovigilance and Risk Management Strategies Conference

Global Pharmacovigilance and Risk Management Strategies Conference is now fully virtual. Join us from the comfort of your own space!


Speakers

  • Stephen  Knowles, MD, MRCP

    Stephen Knowles, MD, MRCP

    • Chief Medical Officer
    • Halozyme Therapeutics, United States

    Steve received his MD from the University of Newcastle Upon Tyne, UK and worked in the UK National Health Service for 17 yrs. He joined Halozyme in 2018 as Vice President, Drug Safety & Pharmacovigilance and became Chief Medical Officer in January 2020, with responsibility for Drug Safety, Medical and Regulatory. Prior to this, Steve worked at Eli Lilly for 16 years, 12 years of which was in drug safety in various roles of increasing responsibility involving safety operations and drug safety surveillance

  • Annette S. Williams, MBA, RPh

    Annette S. Williams, MBA, RPh

    • Vice President, Pharmacovigilance
    • IQVIA, United States

    Annette Williams, M.B.A. R.Ph, is Vice President, Global Head of Lifecycle Safety, leading IQVIA’s comprehensive Safety organization, consisting of more than 6,000 professionals worldwide, providing services across the pharmacovigilance spectrum, including: case processing, regulatory reporting, aggregate reporting, signal detection, risk management, medical information, and safety systems. Williams oversees the exploration and adoption of innovative technologies to streamline how Lifecycle Safety manages safety information and subsequent data analytics on behalf of its clients. Prior to IQVIA, she held leadership positions in both CRO and Pharma fields, including Drug Safety Alliance, Teamm Pharmaceuticals, and GSK.

  • Mariette  Boerstoel-Streefland, MD, MBA, MS

    Mariette Boerstoel-Streefland, MD, MBA, MS

    • Senior Vice President Patient Safety, Chief Safety Officer
    • AstraZeneca, United States

    Mariette Boerstoel-Streefland, MD, MBA, MS(epi) is SVP, Chief Safety Officer at AstraZeneca following the Alexion acquisition in 2021. Prior to her current role she was SVP Global Safety at Alexion Pharmaceuticals, Inc. Before that Mariette was SVP, Head of Global Drug Safety at Shire, having been appointed to lead the safety organization after the Baxalta acquisition in 2016. She joined Baxalta two years prior to establish their safety department with the split off from Baxter. Mariette joined the pharmaceutical industry from clinical practice and had a progressive career, holding various leadership positions in drug safety and medical affairs at Organon (now Merck), Mayne Pharma (now Hospira), Forest Labs (now Allergan) for 30 years.

  • James  Buchanan, PharmD

    James Buchanan, PharmD

    • President
    • Covilance LLC, United States

    After entering drug safety at Genentech, Dr. Buchanan created and led drug safety departments at Gilead, Tularik and Nuvelo. He next served with BioSoteria as the head of the medical and safety consulting group. Dr. Buchanan is currently president of Covilance, LLC, a drug safety consulting service. He is also a co-chair for the American Statistical Association Biopharmaceutical Working Group and co-leads the task force developing open-source interactive safety graphics.

  • Cheryl  Campbell, MS

    Cheryl Campbell, MS

    • Associate Director of Executive Operations/Outreach and Communications, OSE,CDER
    • FDA, United States

    Cheryl L. Campbell, M.S., joined the Food and Drug Administration in 2001. She started at FDA’s Center for Biologic Evaluation and Research (CBER) as a Consumer Safety Officer. She was responsible for the regulatory review of FDA applications for in vitro diagnostics. In 2007 she joined the Center for Drug Evaluation and Research (CDER), Office of Surveillance and Epidemiology (OSE). Currently she is the Associate Director of Outreach and Communications in OSE where she manages and coordinates regulatory policy and communications projects. She has a B.A. degree from Temple University, and a M.S. in Regulatory Science from the University of Maryland.

  • E. Stewart  Geary, MD

    E. Stewart Geary, MD

    • Senior Vice President
    • Eisai Co., Ltd., Japan

    Stewart Geary, MD, is Global Safety Officer and a Senior Vice President at Eisai Co., Ltd. He is a Councilor of the Japanese Association of Pharmaceutical Medicine and serves on the Editorial Advisory Boards for Applied Clinical Trials and Pharmaceutical Medicine. A member of CIOMS XII, he also served on the CIOMS VII Working Group on the Development Safety Update Report, CIOMS VIII on Signal Detection, CIOMS on Standardized MedDRA Queries, CIOMS IX on Medicinal Product Risk Management and CIOMS Working Group on Drug-Induced Liver Injury. Dr. Geary is a DIA Fellow, a Fellow of the Academy of Physicians in Clinical Research and an IFAPP Global Fellow in Medicines Development. He earned a BA from Harvard and MD from Stanford Medical School.

  • Jeremy  Jokinen, PhD, MS

    Jeremy Jokinen, PhD, MS

    • Vice President and Head, Global Risk Management and Epidemiology
    • Bristol-Myers Squibb Company, United States

    Jeremy is the Vice President and Head, Global Risk Management and Epidemiology at Bristol Myers Squibb. In this role, he leads a team of scientists and epidemiologists responsible for insights, evidence generation, and risk minimization efforts ensuring the safety of patients worldwide. Jeremy is also active within numerous TransCelerate pharmacovigilance initiatives and is a deputy topic lead for ICH expert working group E19. Jeremy has over 20 years of experience as a statistician in early phase to post-market pharmaceutical, biological, and medical device research. He holds MS and PhD degrees in quantitative psychology from Ohio University.

  • Jamie Ridley Klucken, PharmD, MBA, RPh

    Jamie Ridley Klucken, PharmD, MBA, RPh

    • Health Scientist, Division of Pharmacovigilance, OSE, CDER
    • FDA, United States

    Dr. Klucken earned a B.A. in Business Management and Economics from George Fox University, an MBA and PharmD from Idaho State University, and completed a PGY1 and PGY2 Residency at the Boise VAMC. Prior to joining FDA, she served as a clinical pharmacist for several outpatient family practice and community clinics focusing on chronic disease state management and as an Associate Professor at Shenandoah University. She currently works as a Safety Evaluator in the Division of Pharmacovigilance, monitoring postmarketing adverse events. She is a Board Certified Pharmacotherapy Specialist and a Board Certified Ambulatory Care Pharmacist.

  • Linda J. Scarazzini, MD, RPh

    Linda J. Scarazzini, MD, RPh

    • Vice President, Pharmacovigilance and Patient Safety
    • AbbVie, United States

    She is currently Vice President, Head of Pharmacovigilance and Patient Safety at AbbVie. Prior to joining AbbVie, Dr. Scarazzini served as Director of the Division of Pharmacovigilance in the Office of Pharmacovigilance and Epidemiology, CDER, FDA. She began her career in pharmacovigilance at Sanofi-Aventis, ultimately serving as Associate Vice President of Pharmacovigilance and Risk Management. In 2016, she was selected by her industry peers to serve as the BioPharma Representative on FDA Drug Safety and Risk Management Advisory Committee. Dr Scarazzini’s publications include the recently-released textbook “Pharmacovigilance: A Practical Approach,” as co-author and co-editor along with members of her AbbVie PV team

  • Sarah  Vaughan

    Sarah Vaughan

    • Head of Vigilance Development
    • Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom

    Sarah has worked in pharmacovigilance at the MHRA for the past 15 years, with 6 years as the Pharmacovigilance Information Unit Manager. She has been MHRA representative on the MedDRA Points to Consider Group, and worked on implementation of the 2012 EU Pharmacovigilance legislation. Her current role is the Head of Vigilance Development, focussing on the development and transformation of the Agency's vigilance systems for all medicinal product types. Sarah leads on key projects in the Agency's Patient Safety function, engaging with strategic stakeholders in the UK healthcare system for adverse incident data collection and signal management processes.

  • Annette  Stemhagen, DrPH, FISPE

    Annette Stemhagen, DrPH, FISPE

    • Senior Vice President and Chief Science Officer
    • UBC, United States

    Dr. Annette Stemhagen is an epidemiologist, with over 30 years of public health research experience, including 20 years in the biopharmaceutical industry. She provides strategic consulting in epidemiology, pharmacovigilance, and risk management, and works with UBC teams to develop and implement creative and innovative study design solutions. She has specific expertise in REMS. She has designed and directed implementation of risk intervention programs, risk management evaluation studies, Risk Evaluation and Mitigation Strategies (REMS), and risk minimization programs for EU Risk Management Plans for more than 120 products. She was appointed as the first Industry Representative to the FDA Drug Safety and Risk Management Advisory Committee.

  • Jo  Wyeth, PharmD

    Jo Wyeth, PharmD

    • Associate Director for Postmarket Assessments, OMEPRM, OSE, CDER
    • FDA, United States

    Jo Wyeth is the Associate Director for Postmarket Assessments, serving as a senior-level scientist specializing in the application of risk management principles, leading efforts to implement and oversee medication error pharmacovigilance activities, research and quality assurance activities, and assessment of risk mitigation measures. She also performs complex safety analyses, advises Office and Division management, and provides leadership for planning, program development, policy and program analysis, and the implementation of safety initiatives that support OMEPRM.

  • Updesh  Dosanjh

    Updesh Dosanjh

    • Practice Leader, Technology Solutions
    • IQVIA, United States

    As Practice Leader for Technology Solutions, Dosanjh is responsible for the overarching strategy regarding AI and Machine Learning as it relates to safety/pharmacovigilance. He focuses on the adoption of innovative technologies to help optimize pharmacovigilance activities for better, faster results. He has 25+ years of experience in the management, development, implementation, and operation of processes and systems within the life sciences and other industries. He has worked with WCI, Logistics Consulting Partners, Amersys Systems Limited, and FJ Systems. He holds a Bachelor’s degree in Materials Science from Manchester University and a Master’s degree in Advanced Manufacturing Systems and Technology from Liverpool University.

  • Courtney  Granville, PhD, MPH

    Courtney Granville, PhD, MPH

    • Global Associate Director, Research and Scientific Programs
    • DIA, United States

    As Global Associate Director Research & Scientific Programs, Dr. Granville provides insight, guidance, and a collaborative approach to build DIA’s research and thought leadership to support innovation and building efficiency in drug, device and diagnostics development. She brings 2 decades of regulatory science-related research experience to her role at DIA. Her research career focused on developing data to support regulatory decision making in the fields of tobacco regulatory science, preclinical and molecular toxicology, nonclinical drug development, and public health. She has worked in academic, government, and industry laboratories leading both clinical and non-clinical research studies, assuring IRB and GLP compliance where relevant.

  • Jamie  Portnoff

    Jamie Portnoff

    • Partner, Founder
    • Truliant Consulting, United States

    Jamie Portnoff is a Founder and Partner at Truliant Consulting. Prior to founding Truliant Consulting, Jamie served as Vice President, Business Transformation at Foresight Group International AG and Senior Director and Global Practice Leader at IQVIA. Jamie held various pharmacovigilance operations and compliance roles at Elan Pharma and Hospira. Over the course of her consulting career, Jamie has led and supported large and small-scale transformation projects in pharmacovigilance, regulatory affairs and manufacturing. Jamie graduated from Northwestern University and holds her Regulatory Affairs Certification (RAC-US).

  • Chelsea  O'Connell, MS, RAC

    Chelsea O'Connell, MS, RAC

    • Director, Global Regulatory and R&D Policy
    • Amgen, United States

    Chelsea O’Connell, MS, RAC, joined Amgen in 2011 and is currently a Global Regulatory and R&D Policy Director, where she advances strategic regulatory policy goals by engaging with regulatory authorities, industry, professional associations, and other stakeholders across various policy topics.

  • Barbara  Hendrickson, MD

    Barbara Hendrickson, MD

    • Immunology Therapeutic Area Head, Pharmacovigilance and Patient Safety
    • AbbVie, Inc., United States

    Dr. Barbara Hendrickson is the Immunology Therapeutic Area Head in Pharmacovigilance and Patient Safety. She is a physician with subspecialty training in pediatrics and infectious diseases and has 18 years of pharmaceutical industry experience. Dr. Hendrickson has been involved in several new product and additional indication submissions. She also has participated in numerous clinical trial safety initiatives as well as the implementation of internal data monitoring committees. In addition, she has been a member of multiple cross-disciplinary working groups, including currently co-leading the DIA-ASA Aggregate Safety Assessment Plan Working Group.

  • Vera  Liang, MD

    Vera Liang, MD

    • Sr. Director, Drug Safety Unit Regional Head - APAC
    • Pfizer (China) R&D Co., Ltd., China

    Vera is a pharmaceutical physician with more than 20 years’ experience in the pharmaceutical industry. She joined the industry after receiving her Medical Degree from the Medical School of Fudan University in China. Vera currently works for Pfizer, managing all country safety organizations across the APAC region. Prior to her current role, she was the Disease Area Cluster Lead (DACL) within the global Safety Surveillance and Risk Management organization in Pfizer. Vera is a well-recognized drug safety expert. She has been active in partnering with Chinese Health Authorities, academia, and varied organizations to grow the PV expertise in China.

  • George N. Pajovich, RPh

    George N. Pajovich, RPh

    • VP, Head of Safety Quality and Risk Management
    • Pfizer Inc, United States

    Geo Pajovich is currently Vice President, Head of Product Safety Surveillance and Reporting within the Pharmacovigilance group at Pfizer, Inc. His main responsibilities include systems and processes for ICSRs and aggregate reports. Geo holds a bachelor of Science degree in Pharmacy with over 22 years of experience in Signal Detection, Risk Evaluation and Risk Management, adverse event reporting, Project Management, quality systems, audits/inspections, and training within the pharmaceutical industry.

  • David G Rand, PhD

    David G Rand, PhD

    • Erwin H. Schell Professorship & Professor of Management Science, Sloan School
    • Massachusetts Institute of Technology, United States

  • Carrie  Scott

    Carrie Scott

    • Director, Safety Compliance, Pharmacovigilance and Patient Safety
    • AbbVie Ltd, Portugal

    Currently Director of Global Safety Compliance, with responsibility to set strategic direction for an optimised pharmacovigilance quality management system. Carrie holds a BSc Biochemistry with Pharmacology. Carrie worked at the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, holding a variety of positions, including Pharmacovigilance Inspectorate Operations Manager & Senior Pharmacovigilance Inspector, and other roles in the Enforcement and Post-Licensing Divisions. Carrie took a lead role in the publication of the MHRA's Good Pharmacovigilance Practice Guide and also contributed to the development of the EU Good Vigilance Practice modules. Carrie has also held other PV Compliance and Quality Assurance roles.

  • Patrick M. Caubel, MD, PhD, MBA

    Patrick M. Caubel, MD, PhD, MBA

    • Chief Safety Officer
    • Pfizer, United States

    M.D. degree, with specialization in Gynecology, Obstetrics & Oncology, from the University of Paris XIII, followed by a Ph.D. in Clinical and Experimental Pharmacology from the University of Paris VII and later an M.B.A from Rutgers University. He worked in positions of increasing responsibility first in academia, and subsequently for Merck KgaA in Germany followed by Johnson & Johnson in the United States. Patrick led Global PV at Sanofi-Pasteur (vaccine division of the Sanofi group), before being promoted to Sanofi-Pharma as Global Head of Pharmacovigilance & Epidemiology. Patrick Joined Pfizer in 2014, has numerous publications in the areas of reproductive medicine, epidemiology and pharmacovigilance.

  • Gerald J. Dal Pan, MD, MHS

    Gerald J. Dal Pan, MD, MHS

    • Director, Office of Surveillance and Epidemiology, CDER
    • FDA, United States

    Gerald J. Dal Pan, MD, MHS currently serves as the Director of the Office of Surveillance and Epidemiology in FDA’s Center for Drug Evaluation and Research, where since 2005 he has been responsible for the Center’s programs in adverse event surveillance and analysis, pharmacoepidemiology, risk management, and medication error prevention. He received his MD from Columbia University College of Physicians and Surgeons and his Master of Health Science in Clinical Epidemiology from the Johns Hopkins University School of Hygiene and Public Health. He completed residency training in Internal Medicine at the Hospital of the University of Pennsylvania and in Neurology at the Johns Hopkins Hospital.

  • Georgy  Genov, MD

    Georgy Genov, MD

    • Head of Pharmacovigilance Office, Quality and Safety of Medicines Department
    • European Medicines Agency, Netherlands

    Dr Georgy Genov is qualified as medical practitioner. He joined the pharmaceutical industry in 1998. Since then he has gained experience in Drug Development, Medical Affairs and Pharmacovigilance. In 2010, he joined the Pharmacovigilance and Risk Management team of the European Medicines Agency. At the beginning of 2020 he assumed the role of Head of Signal and Incident Management Office. In 2011 Dr Genov was appointed Head of Pharmacovigilance Office, which provides leadership and coordination across the pharmacovigilance activities of the Agency, including coordinating the EMA pharmacovigilance matrix and the EU-level activities across the Member States.

  • Cynthia  LaCivita, PharmD

    Cynthia LaCivita, PharmD

    • Director, Division of Risk Management, OMEPRM, OSE, CDER
    • FDA, United States

    Cynthia LaCivita earned her undergraduate degree in microbiology and Doctor of Pharmacy from the University of Maryland (U of MD) and completed an oncology residency at the University of Maryland Cancer Center (UMCC). She was an assistant professor in the Department of Pharmacy Practice and Science at the U of MD School of Pharmacy and assistant professor of Oncology at UMCC, Director of Clinical Standards and Quality for the American Society of Health-System Pharmacists (ASHP) and Director of Education and Special Programs for the ASHP Research and Education Foundation. In April 2010 she joined the Food and Drug Administration, she has served as the director of Division of Risk Management (DRISK) since 2015.

  • Mengchun  Li, MD, MPA

    Mengchun Li, MD, MPA

    • Director, Phamacovigilance
    • Global Alliance For TB Drug Development, United States

    Dr. Mengchun Li is the Director of Pharmacovigilance at TB Alliance. In this position, Dr. Li chairs the multidisciplinary safety management team for all compounds and is responsible for clinical safety and pharmacovigilance. Prior to this, Dr. Li worked at Janssen Pharmaceutical company (J&J), both in China and in the US, as a Study Responsible Physician in both Clinical Development and Medical Affairs. Dr. Li is now co-leading the DIA-ASA (American Statistical Association) joint safety working group fostering interdisciplinary collaboration to improve safety evaluation in drug development. Dr. Li received her MD from China Medical University and her Master of Public Administration from Columbia University.

  • Makoto  Miyazaki, MSc

    Makoto Miyazaki, MSc

    • Medical/Data Science, Safety Risk Management, Pharmacovigilance, Japan Developme
    • MSD K.K., Japan

    Makoto Miyazaki (Pharmacist) is currently working as an associate director, Drug Safety / Pharmacoepidemiology at MSD K.K. He earned both Bachelor and Master degree in pharmacology from Tokyo University Japan. In 2011, after experiencing activities for safety and quality of pharmaceutical products in Eli Lilly Japan, he joined MSD K.K. for pharmacovigilance activities of various therapeutic areas including vaccines / infections. He is recently focusing on optimizing a utilization of real-world data (e.g. claims, electronic health records and DPCs) into pharmacovigilance activity, based on his background expertise of pharmacoepidemiology.

  • Magnus  Nord, MD, PhD

    Magnus Nord, MD, PhD

    • Vice President, Global Patient Safety BioPharma
    • AstraZeneca, Sweden

    As Vice President Global Patient Safety BioPharma Magnus leads an organization with physicians & scientists across US, Spain, India and Sweden responsible for clinical safety and PhV from first time in man to post-market surveillance. Magnus joined industry in Early Clin Development. After a period as Project Director at a Swedish government health agency, he rejoined AstraZeneca and has since then held safety roles of increasing seniority in CNS, Respir&Immunol/Inf/Vaccines and CVRM Therapy Areas, as well as in Enabling Safety Science. Magnus has a strong academic background with an adjunct Professorship at the Karolinska Institute where he, before joining industry, led basic-translational-clinical research in parallel to clinical work.

  • Sandra  Quinn, PhD, MEd

    Sandra Quinn, PhD, MEd

    • Chair, Family Science and Senior Associate Director, Maryland Center for Health
    • University of Maryland School of Public Health, United States

  • Nusrat  Sultani

    Nusrat Sultani

    • Associate Director Safety Compliance
    • Abbvie, United States, United States

    I have been in the pharmaceutical industry for 20 years. About half the time focused in clinical trial management and the recent half focused on compliance, mainly supporting PV related audits and inspections. I find inspections and audits to be truly learning experiences and a chance to showcase how well your system and processes function but to also learn what can be even better.

  • Lothar  Tremmel, PhD

    Lothar Tremmel, PhD

    • Vice President, Quantitative Clinical Sciences and Reporting
    • CSL Behring, United States

    Dr. Tremmel worked in the pharmaceutical industry for over 25 years, where he built and led highly effective groups of statisticians, programmers, and data managers. He is currently the VP of Quantitative Clinical Sciences and Reporting at CSL Behring. Recent appointments include Statistical Head for Astra Zeneca’s Diabetes Portfolio, and VP of Statistics and Programing at Incyte. Dr. Tremmel provided technical leadership for >10 successful new drug applications and label extensions in the areas of CNS/Pain, Oncology, digestive / metabolic disease, and orphan diseases. Dr. Tremmel holds a Ph.D. from the university of Giessen, Germany, and he an active contributor to the DIA Safety Statistics Working group.

  • Howard  Chazin, MD, MBA

    Howard Chazin, MD, MBA

    • Director, Division of Clinical Safety and Surveillance, OSCE, OGD, CDER
    • FDA, United States

    Dr. Chazin joined FDA in 2002 and has held several leadership positions related to clinical policy and safety of new drugs, biologics and generics. He is the Director of the Division of Clinical Safety and Surveillance in the Office of Generic Drugs' Office of Safety and Clinical Evaluation. He leads several multidisciplinary teams of physicians, pharmacists, nurses, and data analysts tasked with identifying and assessing emerging complex safety issues related to potentially inferior generic drug products and addressing all Risk Evaluation and Mitigation Strategies for generic drugs. He also provides oversight on assessment of critical aspects related to challenging, controversial and sensitive generic drug safety issues.

  • Julio Guy  Ciolfi Pinto, MD, MBA

    Julio Guy Ciolfi Pinto, MD, MBA

    • Director, Regional Safety Excellence LATAM
    • Alexion, Astrazeneca Rare Disease, Brazil

    Julio Ciolfi, MD, MBA is Director, Regional Safety Excellence Latin America at AstraZeneca Rare Disease, world leader in the rare disease segment. Coming from clinical practice as a neurologist, Julio has 19 years of experience in the pharmaceutical industry, having held many local and regional leadership roles with increasing responsibility at Schering AG, Merck Sharp and Dohme and Bayer in Medical Affairs, Clinical Operations and Pharmacovigilance.

  • Marianne  Hamilton Lopez, PhD, MPA

    Marianne Hamilton Lopez, PhD, MPA

    • Research Director, Value-Based Payment Reform
    • Duke-Margolis Center For Health Policy, United States

    Marianne Hamilton Lopez, PhD, MPA is Research Director of Value-Based Payment Reform at the Duke-Robert J. Margolis, MD, Center for Health Policy. She focuses on value-based payment models for medical products; oversees a multi-stakeholder Consortium; and partners with faculty and external health experts to advance this work. Dr. Hamilton Lopez was previously with the National Academy of Medicine, AcademyHealth, the US Cochrane Center, and US Department of Health and Human Services.

  • Viola  Macolic Sarinic, DrSc, MD, MSc

    Viola Macolic Sarinic, DrSc, MD, MSc

    • PRAC Scientific Lead
    • European Medicines Agency, Netherlands

    Doctorate in Biomedicine and Health Sciences; Specialist of clinical pharmacology and toxicology; Degree in medicine from the University of Zagreb, Croatia She has been Head of HALMED since December 2011. Her field of expertise is pharmacovigilance in which she has been active more than 20 years, and today she is also the Croatian PRAC delegate in EMA. She held more than 50 invited lectures in the fields of pharmacovigilance, regulatory science, pharmacoeconomics and clinical pharmacology

  • Carrie  Nielson, PhD, MPH

    Carrie Nielson, PhD, MPH

    • Observational Research Senior Manager
    • Amgen, United States

    Carrie focuses on design and analytic methods for RWD in the Center for Observational Research at Amgen. Her experience includes descriptive and comparative effectiveness studies to support new indications, label expansion applications, and post-marketing drug utilization and comparative safety studies. In the Center for Observational Research, she guides innovative study designs and analytic methods to combat confounding, time-related biases, and misclassification of exposures and outcomes.

  • Sophie  Radicke, MSc

    Sophie Radicke, MSc

    • Pharmacovigilance Inspector, Inspectorate, Enforcement & Standards
    • Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom

    Sophie has been a pharmacovigilance inspector at the MHRA since January 2018. Prior to joining the GPvP Inspectorate, she was responsible for the assessment of Type IB safety variations in the MHRA’s Vigilance and Risk Management of Medicines division for two years. Before joining the MHRA, Sophie worked in medical information where she also supported quality assurance activities and the accreditation of new staff. Sophie started her career in the pharmaceutical sector when she worked on a regulatory affairs project for a mid-sized pharmaceutical company in Germany. Sophie has an MSc in Forensic Anthropology and a master’s degree in Human Biology during which she specialised in pharmacology, pathology, and virology.

  • Michael  Richardson, MD, FFPM, FRCP

    Michael Richardson, MD, FFPM, FRCP

    • Senior Vice President, WorldWide Patient Safety
    • Bristol-Myers Squibb, United Kingdom

    Michael Richardson has many years of global management experience in research based life Sciences companies. He has worked in major multinational companies’ across the globe both at a Regional management level and heading up Research and Development in Asia. Currently Head of Bristol Myers Squibb’s Pharmacovigilance Function. Prior to this role he headed BMS and Eli Lilly’s Development and Medical Organization across Asia Pacific. Before joining Lilly he worked in a joint venture in Japan, Fujisawa-Fisons setting up their development and quality control organisations and prior to that with Organon laboratories in the UK as Medical Director.

  • Rebecca  Webb

    Rebecca Webb

    • Director, Pharmacovigilance Quality Assurance
    • Abbvie, United Kingdom

    Rebecca is the Director of Pharmacovigilance Quality Assurance at AbbVie, having joined in January 2016. Prior to this Rebecca spent 10 years at the UK Medicines and Healthcare products Regulatory Agency (MHRA) in variety of operational roles within the Vigilance and Risk Management of Medicines division and later as a Senior Pharmacovigilance Inspector within the Inspection, Enforcement and Standards division.

  • Steven A. Anderson, PhD

    Steven A. Anderson, PhD

    • Director, Office of Biostatistics and Epidemiology, CBER
    • FDA, United States

    Steven Anderson, Ph.D., M.P.P., is currently the Director of the Office of Biostatistics and Epidemiology (OBE) at the FDA Center for Biologics Evaluation and Research (CBER). He provides leadership for all CBER statistical, epidemiological and risk assessment programs. He was previously the Associate Director for Risk Assessment and established a program in quantitative risk assessment for biologics and has led numerous risk assessment projects and epidemiological studies.

  • Michele Peake Andrasik, PhD, MEd

    Michele Peake Andrasik, PhD, MEd

    • Director, Social & Behavioral Sciences and Community Engagement
    • Fred Hutchinson Cancer Research Center, United States

    Dr. Michele Andrasik (she/her) is a clinical health psychologist working to build and enhance partnerships with marginalized communities in clinical research, with a focus on ongoing vaccine trials for HIV and COVID-19. She is the Director of Social Behavioral Sciences and Community Engagement for the Fred Hutchinson-based HIV Vaccine Trials Network (HVTN) and the COVID-19 Prevention Network, Senior Staff Scientist in the Fred Hutchinson Vaccine and Infectious Disease Division and an Affiliate Clinical Professor in the Departments of Global Health and Occupational and Environmental Medicine at the University of Washington.

  • Martin  Holm-Petersen

    Martin Holm-Petersen

    • CEO
    • Insife Inc, United States

  • Narayan  Nair

    Narayan Nair

    • Division Director, Division of Epidemiology, CBER
    • FDA, United States

  • Patrick  Spracklin, MBA

    Patrick Spracklin, MBA

    • Senior Director, PV Process, Technology, Data and Innovation
    • AbbVie, Inc., United States

    Pat leads the Process, Technology, Data, and Innovation organization at Abbvie. In this position Pat leads efforts to continuously improve and innovate across Abbvie's PV System. Pat has a BS in Manufacturing Engineering from Bradley University in Peoria, Illinois and an MBA from Lake Forest Graduate School of Management.

  • Krista F. Huybrechts, PhD, MS, FISPE

    Krista F. Huybrechts, PhD, MS, FISPE

    • Associate Professor of Medicine and Epidemiology
    • Brigham and Women's Hospital; Harvard Medical School, United States

    Krista F. Huybrechts is an Associate Professor of Medicine and Epidemiology at Harvard Medical School and Harvard T.H. Chan School of Public Health. She co-directs the Harvard Program on Perinatal and Pediatric Pharmacoepidemiology. Her research centers on generating evidence regarding the safety and effectiveness of prescription medications during pregnancy. Her work focuses on the use of advanced epidemiological and statistical methods applied mainly to large databases derived from health data collected in the context of routine medical care to help address the unique questions regarding benefit-risk trade-off for prescription medication use faced by pregnant women and their providers.

  • Walter  Straus

    Walter Straus

    • Vice-President, Safety & Pharmacovigilance
    • Moderna, United States